Medicare Enrolled

Dr. Viviane Bunin, MD

Rheumatology · Bellevue, WA
Practice pattern: Mixed Practice — Diverse clinical practice across multiple procedure types
Mixed engagement
14100 SE 36TH ST STE 105, Bellevue, WA 98006
4255028772
In practice since 2007 (19 years)
NPI: 1841498003 verify on NPPES ↗
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Bunin from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Bunin? Request a correction or review of any data shown here. Provider portal →

What this data tells you about Dr. Bunin

Dr. Viviane Bunin is a rheumatology specialist in Bellevue, WA, with 19 years of NPI registration. Based on federal Medicare data, Dr. Bunin performed 1,398 Medicare services across 136 unique beneficiaries.

Between the years covered by Open Payments, Dr. Bunin received a total of $29,705 from 33 pharmaceutical and/or device companies across 650 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in rheumatology. The majority of payments are for speaking programs and promotional activities, reflecting participation in industry-sponsored events. Patients may wish to discuss these relationships with their provider.

The Data Coverage level for Dr. Bunin is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.

✓ 19 years in practice ▲ Top 38% volume in WA $29,705 industry payments

Medicare Practice Summary

Medicare Utilization ↗
1,398
Medicare services
Top 38% in WA for rheumatology
136
Unique beneficiaries
$37
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~74 Medicare services per year of practice

Top procedures by volume

Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.

Procedure Volume Avg. paid Avg. submitted
Denosumab injection (Prolia/Xgeva) 1,080 $18 $70
Office visit, established patient, complex (40-54 min)
An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter.
148 $125 $364
Drug injection, under skin or into muscle
A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle.
63 $12 $183
Intravenous chemotherapy infusion, 1 hour or less
Administration of chemotherapy medication directly into a vein. The procedure takes one hour or less to complete.
55 $123 $1,000
Office visit, established patient (30-39 min)
A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition.
28 $91 $270
New patient office visit, complex (60-74 min) 24 $162 $521
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
3.9% high complexity
81.8% medium
14.3% routine

Industry Payment Transparency

Open Payments through 2024 ↗
$29,705
Total received (2018-2024)
Avg $4,244/year across 7 years
Top 8% in WA for rheumatology
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
33
Companies
650
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →

Payment profile

Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.

Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$11,232 (37.8%)
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$9,820 (33.1%)
Consulting
Expert advisory fees, typically reflecting recognized clinical expertise
$8,653 (29.1%)

Payment trend by year

Annual totals from pharmaceutical and medical device companies.

2024
$6,342
2023
$2,805
2022
$1,711
2021
$1,450
2020
$3,743
2019
$8,452
2018
$5,202

Payments by company (2024)

Consulting
Speaking
Meals & Travel
Research
UCB, Inc.
$1,842
AstraZeneca Pharmaceuticals LP
$1,811
Janssen Biotech, Inc.
$1,602
Amgen Inc.
$239
ABBVIE INC.
$161
Aurinia Pharma U.S., Inc.
$148
PFIZER INC.
$124
ANI Pharmaceuticals, Inc.
$67
E.R. Squibb & Sons, L.L.C.
$64
GENZYME CORPORATION
$61
SOBI, INC
$61
Lilly USA, LLC
$48
Mallinckrodt Hospital Products Inc.
$31
Kyowa Kirin, Inc.
$27
Novartis Pharmaceuticals Corporation
$22
Sandoz Inc.
$19
GlaxoSmithKline, LLC.
$14
Top 3 companies account for 82.9% of 2024 payments
All-time payments by company (2018-2024) ›
AbbVie, Inc.
$7,882
UCB, Inc.
$4,863
AbbVie Inc.
$3,955
Janssen Biotech, Inc.
$3,077
AstraZeneca Pharmaceuticals LP
$2,175
Novartis Pharmaceuticals Corporation
$1,363
PFIZER INC.
$1,227
Amgen Inc.
$925
Horizon Therapeutics plc
$531
GlaxoSmithKline, LLC.
$443
ABBVIE INC.
$433
Lilly USA, LLC
$413
E.R. Squibb & Sons, L.L.C.
$407
Mallinckrodt Hospital Products Inc.
$298
Biogen, Inc.
$250
Genentech USA, Inc.
$230
Aurinia Pharma U.S., Inc.
$225
Horizon Pharma plc
$160
SOBI, INC
$147
GENZYME CORPORATION
$129
Regeneron Healthcare Solutions, Inc.
$110
Alexion Pharmaceuticals, Inc.
$72
ANI Pharmaceuticals, Inc.
$67
Fresenius Kabi USA, LLC
$49
Sobi, Inc
$49
Ultragenyx Pharmaceutical Inc.
$49
Boehringer Ingelheim Pharmaceuticals, Inc.
$45
Sandoz Inc.
$41
Kyowa Kirin, Inc.
$27
Octapharma USA, Inc.
$22
Novo Nordisk Inc
$18
Exeltis, USA Inc.
$12
Celgene Corporation
$12
Top 3 companies account for 56.2% of all-time payments
Associated products mentioned in payments ›
ACTHAR · AMJEVITA · Actemra · BENLYSTA · Bimzelx · COSENTYX · CRYSVITA · CYLTEZO · Cimzia · Crysvita · DUPIXENT · EVENITY · Enbrel · FORTEO · HUMIRA · HYRIMOZ · Humira · IDACIO · INFLECTRA · KEVZARA · KEVZARA SARILUMAB INJECTION · KINERET · KRYSTEXXA · Kineret · LUPKYNIS · LYRICA · NUCALA · OCTAGAM IMMUNE GLOBULIN (HUMAN) · ORENCIA · Otezla · PANZYGA · PURIFIED CORTROPHIN GEL · RAYOS · REMICADE · RINVOQ · Rinvoq · Rituxan · SAPHNELO · SIMPONI ARIA · SKYRIZI · STELARA · STRENSIQ · Saxenda · TALTZ · TAVNEOS · TECFIDERA · TREMFYA · TYSABRI · Tavneos · XELJANZ
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →

The majority of payments (38%) are for speaking programs and promotional activities, which reflect participation in industry-sponsored educational or marketing events. This is common in rheumatology and does not inherently indicate bias, but patients may wish to be aware. Total industry engagement is in the top 8% for rheumatology in WA.

Looking for a rheumatology specialist in Bellevue?
Compare rheumatologists in the Bellevue area by procedure volume, costs, and industry payment transparency.
Browse rheumatologists nearby

Geographic Context

Rheumatologists within 10 mi
93
Per 100K population
4.1
County median income
$122,148
Nearest hospital
OVERLAKE HOSPITAL MEDICAL CENTER
5.2 mi

Data Sources

Provider Registry NPPES Weekly updates
Medicare Enrollment PECOS Monthly updates
Practice Data Medicare Util. Annual (CY lag)
Industry Payments Open Payments CY 2024
Disciplinary History — Not public N/A

This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →

Summary

Dr. Bunin is a mixed practice specialist, with moderate Medicare volume, with mixed engagement industry engagement in the top 8% of WA peers, with 19 years of NPI registration.

This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →

Frequently Asked Questions

Is Dr. Bunin experienced with denosumab injection (prolia/xgeva)?
Based on Medicare claims data, Dr. Bunin performed 1,080 denosumab injection (prolia/xgeva) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Bunin receive payments from pharmaceutical companies?
Yes. Dr. Bunin received a total of $29,705 from 33 companies across 650 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Bunin's costs compare to other rheumatologists in Bellevue?
Dr. Bunin's average Medicare payment per service is $37. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Bunin) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
About this page

All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.

This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.

Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology

Data Disclaimer — Data sourced from the Centers for Medicare & Medicaid Services (CMS): National Plan and Provider Enumeration System (NPPES), Open Payments program, Medicare Provider Utilization and Payment Data, and Provider Enrollment & Certification data (PECOS). Published under the Freedom of Information Act (FOIA). This website is not affiliated with, endorsed by, or authorized by CMS, HHS, or the U.S. Government. Data may contain errors as reported to CMS by providers and reporting entities. Payments from industry are legal and do not indicate wrongdoing. Medicare data reflects only patients aged 65+ or those with qualifying disabilities. For corrections, contact CMS directly. This information does not constitute medical advice and should not be used as the sole basis for choosing a healthcare provider. Procedure descriptions use plain language and do not reference CPT® codes, which are copyrighted by the American Medical Association. Full methodology → · Report a data error → · Privacy policy →